BMO Capital Maintains Outperform on Centessa Pharmaceuticals, Maintains $15 Price Target
Portfolio Pulse from Benzinga Newsdesk
BMO Capital analyst Kostas Biliouris has maintained an Outperform rating on Centessa Pharmaceuticals (NASDAQ:CNTA) with a price target of $15.
April 01, 2024 | 4:25 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
BMO Capital maintains an Outperform rating on Centessa Pharmaceuticals with a $15 price target.
The reaffirmation of an Outperform rating and a $15 price target by a reputable analyst like Kostas Biliouris from BMO Capital is likely to instill confidence among investors and could lead to a positive short-term price movement for Centessa Pharmaceuticals.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100